Clinical Trials
2 trialsNCT05879484 2025-07-10
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT04536922 2021-02-01
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn